Here we present the description of a new series in which has been performed the analysis of mutations in KRAS and NRAS genes.MethodsSamples of 108 patients with colorectal cancer were used. DNA were extracted from formalin fixed paraffin embedded samples using COBAS DNA sample preparation kit (...
KRAS MutationNoonan SyndromeNRAS MutationNext Generation Sequencing MethodBackgroundOverall survival of metastatic colorectal cancer (mCRC) patients has been improved with the addition of targeted therapy such as anti-epithelial growth factor receptor monoclonal antibodies (anti-EGFR mAbs) to standard ...
However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer. 2001 Cancer Research Campaignhttp://...
Cancer SciencePrognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer. Sasaki Y,Akasu T,Saito N,et al. Cancer Science . 2016Sasaki Y,Akasu T,Saito N,et al.Prognostic and predictive value of extended RAS mutation and mismatch repair ...
CONCLUSIONS: K-ras abnormalities can be detected in circulating DNA extracted from the plasma specimens of patients with colorectal cancer. If these results are confirmed in larger studies, genetic analysis of plasma DNA may have clinical applications in the future. (Gastroenterology 1997 Apr;112(4)...
Although previous attempts to therapeutically target RAS proteins — which are frequently mutationally activated in cancer — have been unsuccessful, recent advances in our understanding of these signalling proteins have led to a renewed interest in RAS-
RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge is the fact that direct inhibition of RAS proteins has proved difficult, leading researchers to test numerous alternative...
RAS mutations, such as KRASG12Dand KRASG12V, in difficult to treat cancers, including pancreatic, colorectal, lung and endometrial cancer types. KRAS inhibitors have been developed to target the KRASG12Cmutation, but these therapies are limited to only around ten percent of KRAS-driven cancers...
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23(9):2313-2318. doi:10.1093/annonc/mdr623 PubMedGoogle ScholarCrossref 5. Mauri G, Pizzutilo EG, Amatu A, et al. Retreatment with anti-EGFR ...
Although immunotherapy has changed the treatment strategy for many cancers with great success, patients with microsatellite stable (MSS) and RAS-mutant metastatic colorectal cancer (mCRC) especially with liver metastases have a...